The first domestic targeted il-36r monoclonal antibody was administered to the first subject in New Zealand
According to the official account of WeChat, Shanghai, China's Limited by Share Ltd has announced that the HB0034 project, the first recombinant IL-36R monoclonal antibody against human IL-36R, has been completed in New Zealand. The phase ia clinical study conducted in New Zealand aims to evaluate the safety, tolerance, immunogenicity and pharmacokinetics of hb0034 in healthy subjects. Huaaotai biology is a subsidiary of Huahai pharmaceutical, a listed company.
This text is a result of machine translation.
Related companies：
In-depth
Technology
Exclusive Interview with Liu Di, Managing Director of Peakview Capital
“We thought this battle would be over in one or two years, but it has been dragging on for three years, so this could conversely be an opportunity for us to focus on; in other words, amid the unexpected international and domestic situation, new opportunities will be seen.”
Yesterday 12:51 PM
May 02, 2022 07:50 PM
Apr 18, 2022 09:14 PM
Apr 18, 2022 06:30 PM
Apr 11, 2022 08:42 PM
Technology
China Launch Startup Orienspace Raises Nearly USD 60 Mn in Series A Round
Facing the explosive demand of various satellite networks, Orienspace innovatively builds the “Gravity” series of medium-and-large-sized commercial launch vehicles, achieving the economies of scale
Yesterday 07:50 PM
Technology
Smart Mining Truck Maker Easymove Raises Tens of Mns of CNY in Angel Round
With the development of new energy industry, huge opportunities existed in vehicle electrification under different mobile scenarios, and construction machinery is one of the largest potential markets
Yesterday 02:29 PM
Technology
Cross-border Marketing Firm Brandgogo Raises Nearly Tens of Mns of CNY in Angel Round
With the intense competition in the cross-border e-commerce industry, overseas traffic and marketing costs are increasing. Meanwhile, due to differences in language and culture, Chinese cross-border vendors are not accustomed to overseas marketing
May 20, 2022 09:23 PM
Briefing Aug 26, 2021 06:31 PM
· Healthcare
Huahai pharmaceutical: the net profit in the first half of the year was 516 million yuan, a year-on-year decrease of 10.84%
See more
Read next
In-depth
Technology
Exclusive Interview with Liu Di, Managing Director of Peakview Capital
Yesterday 12:51 PM
In-depth
In-depth
EqualOcean is an information service provider and investment research company that aims to become a global platform for industrial innovation. Founded in February 2014 and headquartered in Beijing, with a client network covering over 50 countries, the firm provides comprehensive professional services, including industry research, investment analysis, innovation consulting, data products, corporate branding and international strategy.